Gross Margin - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.2 PLN -0.18% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Gross Margin
Ryvu Therapeutics SA

56.8%
Current
-100%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.8%
=
Gross Profit
31.6m
/
Revenue
55.6m

Gross Margin Across Competitors

Country PL
Market Cap 1.3B PLN
Gross Margin
57%
Country US
Market Cap 1.4T USD
Gross Margin
55%
Country US
Market Cap 234.3B USD
Gross Margin
41%
Country US
Market Cap 200B USD
Gross Margin
59%
Country KR
Market Cap 70.5T KRW
Gross Margin
50%
Country CH
Market Cap 40B CHF
Gross Margin
29%
Country US
Market Cap 43.7B USD
Gross Margin
35%
Country US
Market Cap 39.9B USD
Gross Margin
55%
Country US
Market Cap 29.6B USD
Gross Margin
59%
Country IE
Market Cap 24.5B USD
Gross Margin
30%
Country US
Market Cap 21.5B USD
Gross Margin
36%

Profitability Report

View the profitability report to see the full profitability analysis for Ryvu Therapeutics SA.

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.8%
=
Gross Profit
31.6m
/
Revenue
55.6m
What is the Gross Margin of Ryvu Therapeutics SA?

Based on Ryvu Therapeutics SA's most recent financial statements, the company has Gross Margin of 56.8%.